Cellular and molecular functions of SETD2 in the central nervous system.

J Cell Sci

The School of Biomedical Sciences, University of Queensland, Brisbane, Queensland 4072, Australia.

Published: November 2023

The covalent modification of histones is critical for many biological functions in mammals, including gene regulation and chromatin structure. Posttranslational histone modifications are added and removed by specialised 'writer' and 'eraser' enzymes, respectively. One such writer protein implicated in a wide range of cellular processes is SET domain-containing 2 (SETD2), a histone methyltransferase that catalyses the trimethylation of lysine 36 on histone H3 (H3K36me3). Recently, SETD2 has also been found to modify proteins other than histones, including actin and tubulin. The emerging roles of SETD2 in the development and function of the mammalian central nervous system (CNS) are of particular interest as several SETD2 variants have been implicated in neurodevelopmental disorders, such as autism spectrum disorder and the overgrowth disorder Luscan-Lumish syndrome. Here, we summarise the numerous roles of SETD2 in mammalian cellular functions and development, with a focus on the CNS. We also provide an overview of the consequences of SETD2 variants in human disease and discuss future directions for understanding essential cellular functions of SETD2.

Download full-text PDF

Source
http://dx.doi.org/10.1242/jcs.261406DOI Listing

Publication Analysis

Top Keywords

setd2
8
functions setd2
8
central nervous
8
nervous system
8
roles setd2
8
setd2 variants
8
cellular functions
8
cellular
4
cellular molecular
4
functions
4

Similar Publications

Renal cell carcinoma (RCC) is a malignant tumor with highly heterogeneous and complex molecular mechanisms. Through systematic analysis of TCGA, COSMIC and other databases, 24 mutated genes closely related to RCC were screened, including VHL, PBRM1, BAP1 and SETD2, which play key roles in signaling pathway transduction, chromatin remodeling and DNA repair. The PI3K/AKT/mTOR signaling pathway is particularly important in the pathogenesis of RCC.

View Article and Find Full Text PDF

To evaluate the predictive utility of N6-methyladenosine (m6A)-associated long non-coding RNAs (lncRNAs) for the prognosis and immunotherapy response in papillary renal cell carcinoma (pRCC). Transcriptomic data of pRCC samples were extracted from the TCGA database. The m6A-related lncRNAs were identified by Pearson correlation analysis.

View Article and Find Full Text PDF

Tumor infiltrating T-cells and loss of expression of SWI/SNF genes in varying stages of clear cell renal cell carcinoma.

Pathol Res Pract

December 2024

Department of Pathology and Genomic Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, United States; Physician Sciences Medical Group, Norfolk General Hospital, Norfolk, VA, United States.

Background: Patients with clear cell renal cell carcinoma (ccRCC) metastases face poor prognoses, even with adjuvant therapies. Tumor-infiltrating T-cells and macrophages are critical in targeting tumor cells within the renal microenvironment. Beyond VHL mutations, loss-of-function mutations in SWI/SNF complex genes, including PBRM1, BAP1, ARID1A, SETD2, SMARCA4 (BRG1), and SMARCA2 (BRM), have been implicated in ccRCC progression.

View Article and Find Full Text PDF
Article Synopsis
  • Osteosarcoma exhibits distinct genetic features between younger and elderly patients, influencing their treatment responses.
  • Genetic analysis of 204 patients revealed specific mutations associated with age, indicating that younger patients tend to have alterations like CCNE1 and MYC, while older patients show changes like CDK4 and MDM2.
  • The study concludes that understanding these genetic differences could enhance chemotherapy selection and treatment strategies for osteosarcoma, advocating for the early use of cancer genome profiling.
View Article and Find Full Text PDF

Background: In CLEAR, lenvatinib + pembrolizumab (L+P) significantly improved efficacy versus sunitinib in first-line treatment of patients with advanced renal cell carcinoma (RCC). We report results from CLEAR biomarker analyses.

Methods: PD-L1 immunohistochemistry (IHC) and next-generation sequencing assays (whole exome sequencing/RNA-sequencing) were performed on archival tumor specimens.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!